Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03373591 · ClinicalTrials.gov registry record · Phase 2
Liposomal Bupivacaine in Bariatric Surgery
A Phase 2 study of Bariatric Surgery Analgesia, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 219
- Enrollment target
- 1
- Study location
NCT03373591 is a Phase 2 study of Bariatric Surgery Analgesia that has completed, run by Montefiore Medical Center. The registered enrollment target is 219 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03373591, a Phase 2 study of Bariatric Surgery Analgesia, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 219 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to perform a randomized controlled trial for patients undergoing bariatric surgery, comparing the need for opiates with and without administration of a transversus abdominis plane (TAP) block using the long acting local anesthetic, liposomal bupivacaine (Exparel®). From this study, the investigators will assess whether use of long acting local anesthetic can reduce the need for opiates in the bariatric population.
Conditions Studied
Interventions
- DRUG Liposomal Bupivacaine TAP block
- DRUG Bupivacaine TAP block
Study Locations (1)
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 219 participants |
| Start Date | 2018-01-30 |
| Est. Completion | 2018-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03373591
The ClinicalTrials.gov registry entry for NCT03373591 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 219 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bariatric Surgery Analgesia appearing as the primary indexed condition, and to 2 interventions - of which Liposomal Bupivacaine TAP block is the first listed.
NCT03373591 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03373591 about?
NCT03373591 is a clinical study titled "Liposomal Bupivacaine in Bariatric Surgery". The aim of this study is to perform a randomized controlled trial for patients undergoing bariatric surgery, comparing the need for opiates with and without administration of a transversus abdominis plane (TAP) block using the long acting local anesthetic, liposomal bupivacaine (Exparel®). From this...
What is the current status of trial NCT03373591?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 219 participants. The study started on 2018-01-30. Estimated completion is 2018-12-31.
What conditions does trial NCT03373591 study?
This clinical trial studies the following conditions: Bariatric Surgery Analgesia.
What interventions are being tested in trial NCT03373591?
The interventions under investigation include: Liposomal Bupivacaine TAP block (DRUG), Bupivacaine TAP block (DRUG).
Who is sponsoring clinical trial NCT03373591?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03373591 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.